CN117940771A - 用于评估候选药剂的治疗性质的方法和模型系统以及相关的计算机可读介质和系统 - Google Patents

用于评估候选药剂的治疗性质的方法和模型系统以及相关的计算机可读介质和系统 Download PDF

Info

Publication number
CN117940771A
CN117940771A CN202280061668.XA CN202280061668A CN117940771A CN 117940771 A CN117940771 A CN 117940771A CN 202280061668 A CN202280061668 A CN 202280061668A CN 117940771 A CN117940771 A CN 117940771A
Authority
CN
China
Prior art keywords
cell
cells
balanced
cell types
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280061668.XA
Other languages
English (en)
Chinese (zh)
Inventor
H·古达兹
约翰尼·余
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CN117940771A publication Critical patent/CN117940771A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Computing Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280061668.XA 2021-07-23 2022-07-22 用于评估候选药剂的治疗性质的方法和模型系统以及相关的计算机可读介质和系统 Pending CN117940771A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163225209P 2021-07-23 2021-07-23
US63/225,209 2021-07-23
PCT/US2022/038069 WO2023004149A1 (en) 2021-07-23 2022-07-22 Methods and model systems for assessing therapeutic properties of candidate agents and related computer readable media and systems

Publications (1)

Publication Number Publication Date
CN117940771A true CN117940771A (zh) 2024-04-26

Family

ID=84979606

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280061668.XA Pending CN117940771A (zh) 2021-07-23 2022-07-22 用于评估候选药剂的治疗性质的方法和模型系统以及相关的计算机可读介质和系统

Country Status (5)

Country Link
US (1) US20250003953A1 (cg-RX-API-DMAC7.html)
EP (1) EP4374169A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024529939A (cg-RX-API-DMAC7.html)
CN (1) CN117940771A (cg-RX-API-DMAC7.html)
WO (1) WO2023004149A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118692590B (zh) * 2024-07-23 2024-12-27 浙江大学 基于单细胞转录组图谱的药物筛选分析方法、介质及设备
WO2026117171A1 (en) 2024-11-26 2026-06-04 Samuelsson Erik Reinhold Method for developing a cancer organoid digital twin for combinatorial therapeutic efficacy prediction and system and applications associated therewith

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518035B1 (en) * 1998-06-02 2003-02-11 Rosetta Inpharmatics, Inc. Targeted methods of drug screening using co-culture methods
CA2950559C (en) * 2014-05-30 2023-09-19 Kuraray Co., Ltd. Culture method and cell cluster
US20190114390A1 (en) * 2017-10-13 2019-04-18 BioAge Labs, Inc. Drug repurposing based on deep embeddings of gene expression profiles
WO2021046027A1 (en) * 2019-09-02 2021-03-11 The Broad Institute, Inc. Rapid prediction of drug responsiveness
US20220404340A1 (en) * 2019-10-25 2022-12-22 Massachusetts Institute Of Technology Methods and compositions for high-throughput compressed screening for therapeutics

Also Published As

Publication number Publication date
US20250003953A1 (en) 2025-01-02
JP2024529939A (ja) 2024-08-14
WO2023004149A1 (en) 2023-01-26
EP4374169A1 (en) 2024-05-29
EP4374169A4 (en) 2025-06-11

Similar Documents

Publication Publication Date Title
Raghavan et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
Barkley et al. Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment
Goveia et al. An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates
Kouros-Mehr et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model
CN109072309B (zh) 癌症进化检测和诊断
WO2021183917A9 (en) Systems and methods for deconvolution of expression data
Chen et al. Identification of HCG18 and MCM3AP-AS1 that associate with bone metastasis, poor prognosis and increased abundance of M2 macrophage infiltration in prostate cancer
Wang et al. Single-cell transcriptome analysis revealing the intratumoral heterogeneity of ccRCC and validation of MT2A in pathogenesis
Chen et al. Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine
US20250003953A1 (en) Methods and Model Systems for Assessing Therapeutic Properties of Candidate Agents and Related Computer Readable Media and Systems
JP7220711B2 (ja) 病態の核酸ベースのリアルタイム判定のための方法及び装置
Milling et al. Framework for in vivo T cell screens
Yen et al. Genomic and molecular signatures of successful patient-derived xenografts for oral cavity squamous cell carcinoma
Yang et al. Enhancing metastatic colorectal cancer prediction through advanced feature selection and machine learning techniques
Audesse et al. FOXO3 regulates a common genomic program in aging and glioblastoma stem cells
Chan et al. Mutational order and epistasis determine the consequences of FBXW7 mutations during colorectal cancer evolution
Lin et al. LncRNA DIRC1 is a novel prognostic biomarker and correlated with immune infiltrates in stomach adenocarcinoma
KR20180000991A (ko) 환자특이적 환자 유래 세포의 제조방법 및 이의 이용
Winkler et al. Dissecting the contributions of tumor heterogeneity on metastasis at single-cell resolution
Chaudhary et al. Activation of KrasG12D in subset of alveolar type II cells enhances cellular plasticity in lung adenocarcinoma
Andreatta et al. Projecting single-cell transcriptomics data onto a reference T cell atlas to interpret immune responses
WO2024192567A1 (zh) 建立新型人肠道及结直肠肿瘤类器官培养体系
CN108998532A (zh) 一种直肠腺癌的诊治标志物
Yu et al. Bioinformatic analysis the expression and clinical significance of CDRT15 in cholangiocarcinoma using TCGA database
Sun et al. The METTL3 inhibitor STM2457 suppresses gastric cancer progression by modulating m6A RNA modification

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination